The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• BEZ235 is an orally available dual inhibitor of phosphatidylinositol 3-kinase (PI(3)K) and mammalian target of rapamycin (mTOR).
• BEZ235 has demonstrated efficacy in various cancer types in vitro and has advanced to clinical trials for solid tumors.
• The PI3K/mTOR pathway is frequently dysregulated in cancer, making it a key therapeutic target.

Purpose of the Study:

• To evaluate the efficacy of BEZ235 in human lung cancer cell lines.
• To determine if BEZ235 affects key signaling pathways involved in lung cancer proliferation.
• To assess the potential synergistic effects of BEZ235 in combination with cisplatin.

Main Methods:

• Analysis of human lung cancer cell lines (EPLC, HCC, H1339) using fluorescence in situ hybridization, gene sequencing, and Western blot.
• Treatment of cell lines with BEZ235 and/or cisplatin.
• Quantification of cell survival fraction post-treatment.

Main Results:

• BEZ235 treatment reduced pAkt and pS6 expression, indicating inhibition of the epidermal growth factor (EGF) pathway.
• BEZ235 demonstrated significant inhibition of lung tumor cell growth.
• The combination of BEZ235 and cisplatin showed additive effects on tumor cell growth inhibition.
• Efficacy was observed independently of EGFR amplification and mutations in EGFR, KRAS, PI3K, or AKT.

Conclusions:

• The dual PI3K/mTOR inhibitor BEZ235 is effective against lung cancer cell lines.
• BEZ235 demonstrates potential as a therapeutic agent for lung cancer.
• Further investigation in clinical phase I studies is warranted for BEZ235 in lung cancer patients.